Charted: Lofty expectations

Amgen today said its experimental obesity drug, MariTide, helped patients lose up to 20% of their weight in a year, with no plateau.

• The stock dropped nearly 5%.

The big picture: Expectations around MariTide were sky high.

• The drug is taken by injection once a month, compared to once a week for the popular GLP-1 drugs on the market.

The bottom line: Analysts had set the bar at a 25% weight-loss figure from the yearlong mid-stage trial in order for MariTide to compete with Eli Lilly and Novo Nordisk's coming second-generation drugs, per Bloomberg.